NeuroTherapia announces completion of its Phase 2a Trial of a novel treatment for Alzheimer’s Disease

B Trial Designed to Demonstrate Target Engagement, Safety, and Pharmacokinetics CLEVELAND, April 7, 2026 /PRNewswire/ — NeuroTherapia, Inc., a clinical-stage company focused on developing oral therapies…
posteditor
posteditor
Articles: 16137

Other News